Psy4 - Response to Induction Therapy, Treatment Adverse Events and Healthcare Resource Use in Incident Anca-Associated Vasculitis (Aav) Patients

Value in Health- United Kingdom

doi 10.1016/j.jval.2018.09.2581

Full Text

Abstract

Available in

Categories

Occupational Health

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

Psy78 - The Economic and Healthcare Burden of Anca-Associated Vasculitis (Aav) in Germany

Value in Health

Occupational Health

English

Psy5 - Patients With Relapsing Anca-Associated Vasculitis (Aav) Experience Unmet Needs and Utilise Significant Healthcare Resources

Value in Health

Occupational Health

English

AB0597 Low-Dose Rituximab as Induction Therapy for Japanese Patients With Anca-Associated Vasculitis

English

Anca-Associated Vasculitis

The Journal of scientific articles Health and Education millennium

English

Venous Thrombotic Events in ANCA-associated Vasculitis: Incidence and Risk Factors

English

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis

Kidney International Reports

English

Correction To: Serious Adverse Events and Fatal Adverse Events Associated With Nivolumab Treatment in Cancer Patients

Journal for ImmunoTherapy of Cancer

Molecular Medicine

Cancer Research

English

Genetics of ANCA-Associated Vasculitis

Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis

English

Microscopic Haematuria in ANCA-Associated Vasculitis With Glomerulonephritis During Treatment and Remission

Journal of Vasculitis

English